Physician profile
John Robert Winningham
NPI 1922489483
$1,533.20
in general payments reported to CMS, 2019-2025
28 companies · $158 in 2025
The $158 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.98 · 2020: $100 · 2021: $409 · 2022: $387 · 2023: $260 · 2024: $196 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.83 | 2021-2025 | Wegovy, Saxenda |
| Glaxosmithkline, LLC. | $225.02 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $117.11 | 2019-2023 | Belsomra |
| Corium, LLC | $107.90 | 2022-2023 | Azstarys |
| Antares Pharma, INC. | $105.64 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $67.79 | 2022 | |
| Supernus Pharmaceuticals, INC. | $57.74 | 2024-2025 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $54.42 | 2021 | |
| Phathom Pharmaceuticals, INC. | $51.18 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $49.36 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.45 | 2019-2022 | |
| Pfizer INC. | $40.37 | 2021-2023 | |
| Sanofi Pasteur INC. | $37.34 | 2024-2025 | |
| Kaleo, INC. | $31.39 | 2021 | |
| Lilly USA, LLC | $27.21 | 2021-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.70 | 2020-2021 | |
| Uswm, LLC | $19.00 | 2021 | |
| Bausch Health US, LLC | $18.05 | 2022 | |
| Dexcom, INC. | $17.08 | 2024 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $16.05 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $15.25 | 2020 | |
| Sobi, INC | $15.12 | 2022 | |
| Esperion Therapeutics, INC. | $15.03 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $14.45 | 2025 | Breztri |
| Amarin Pharma, INC. | $14.42 | 2021 | |
| Becton, Dickinson and Company | $13.74 | 2025 | Bd Onclarity |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2024 | Zoryve |
| Amgen INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Winningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.